Amylyx Pharmaceuticals (AMLX) Competitors $5.38 +0.27 (+5.36%) As of 12:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMLX vs. ANIP, APGE, IMCR, KNSA, IRON, SPRY, EWTX, VERA, TVTX, and GPCRShould you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include ANI Pharmaceuticals (ANIP), Apogee Therapeutics (APGE), Immunocore (IMCR), Kiniksa Pharmaceuticals (KNSA), Disc Medicine (IRON), ARS Pharmaceuticals (SPRY), Edgewise Therapeutics (EWTX), Vera Therapeutics (VERA), Travere Therapeutics (TVTX), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry. Amylyx Pharmaceuticals vs. ANI Pharmaceuticals Apogee Therapeutics Immunocore Kiniksa Pharmaceuticals Disc Medicine ARS Pharmaceuticals Edgewise Therapeutics Vera Therapeutics Travere Therapeutics Structure Therapeutics Amylyx Pharmaceuticals (NASDAQ:AMLX) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, community ranking, institutional ownership, valuation, dividends and profitability. Does the MarketBeat Community favor AMLX or ANIP? ANI Pharmaceuticals received 405 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. However, 67.31% of users gave Amylyx Pharmaceuticals an outperform vote while only 64.14% of users gave ANI Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAmylyx PharmaceuticalsOutperform Votes3567.31% Underperform Votes1732.69% ANI PharmaceuticalsOutperform Votes44064.14% Underperform Votes24635.86% Which has more risk & volatility, AMLX or ANIP? Amylyx Pharmaceuticals has a beta of -0.53, suggesting that its share price is 153% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Is AMLX or ANIP more profitable? Amylyx Pharmaceuticals has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.28%. ANI Pharmaceuticals' return on equity of 15.87% beat Amylyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amylyx PharmaceuticalsN/A -36.97% -29.61% ANI Pharmaceuticals -1.28%15.87%6.88% Do institutionals & insiders have more ownership in AMLX or ANIP? 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 12.7% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts rate AMLX or ANIP? Amylyx Pharmaceuticals presently has a consensus target price of $8.00, indicating a potential upside of 48.59%. ANI Pharmaceuticals has a consensus target price of $80.13, indicating a potential upside of 14.44%. Given Amylyx Pharmaceuticals' higher possible upside, research analysts plainly believe Amylyx Pharmaceuticals is more favorable than ANI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amylyx Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86ANI Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media prefer AMLX or ANIP? In the previous week, ANI Pharmaceuticals had 2 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 9 mentions for ANI Pharmaceuticals and 7 mentions for Amylyx Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.03 beat Amylyx Pharmaceuticals' score of 0.82 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, AMLX or ANIP? Amylyx Pharmaceuticals has higher earnings, but lower revenue than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmylyx Pharmaceuticals$87.37M5.49$49.27M-$4.44-1.21ANI Pharmaceuticals$614.38M2.48$18.78M-$1.14-61.42 SummaryANI Pharmaceuticals beats Amylyx Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMLX vs. The Competition Export to ExcelMetricAmylyx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$479.72M$6.72B$5.49B$7.97BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-1.417.3622.6118.58Price / Sales5.49241.71397.51103.15Price / Cash5.5165.8538.1834.62Price / Book0.846.486.704.26Net Income$49.27M$143.43M$3.22B$248.31M7 Day Performance2.75%1.69%1.26%1.34%1 Month Performance61.20%6.58%3.73%3.92%1 Year Performance178.96%-2.63%15.82%5.33% Amylyx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMLXAmylyx Pharmaceuticals2.8575 of 5 stars$5.38+5.4%$8.00+48.6%+182.3%$479.72M$87.37M-1.41200Upcoming EarningsANIPANI Pharmaceuticals4.4434 of 5 stars$68.00-1.7%$80.13+17.8%+7.3%$1.48B$614.38M-123.64600Positive NewsAPGEApogee Therapeutics2.226 of 5 stars$32.85-0.8%$92.17+180.6%-22.0%$1.48BN/A-13.5791News CoveragePositive NewsIMCRImmunocore3.1973 of 5 stars$29.41+3.5%$63.73+116.7%-49.1%$1.47B$310.20M-30.96320Upcoming EarningsNews CoveragePositive NewsKNSAKiniksa Pharmaceuticals2.4929 of 5 stars$20.05-0.8%$37.17+85.4%+44.1%$1.46B$423.24M-143.20220Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageIRONDisc Medicine2.3683 of 5 stars$42.06-0.3%$93.80+123.0%+77.5%$1.45BN/A-10.5730Upcoming EarningsNews CoveragePositive NewsSPRYARS Pharmaceuticals3.1313 of 5 stars$14.32-3.8%$31.00+116.5%+60.6%$1.41B$89.15M-28.0890Upcoming EarningsNews CoveragePositive NewsHigh Trading VolumeEWTXEdgewise Therapeutics3.2197 of 5 stars$13.30-1.1%$40.13+201.7%-8.6%$1.39BN/A-8.8760Upcoming EarningsAnalyst ForecastShort Interest ↑News CoveragePositive NewsVERAVera Therapeutics2.9227 of 5 stars$21.11-0.8%$64.67+206.3%-40.9%$1.35BN/A-8.0940Upcoming EarningsNews CoveragePositive NewsTVTXTravere Therapeutics2.925 of 5 stars$15.11+1.3%$32.08+112.3%+276.3%$1.34B$233.18M-3.69460News CoveragePositive NewsGPCRStructure Therapeutics2.2116 of 5 stars$23.10+6.2%$81.29+251.9%-31.5%$1.32BN/A-31.22136Upcoming EarningsNews CoverageHigh Trading Volume Related Companies and Tools Related Companies ANI Pharmaceuticals Competitors Apogee Therapeutics Competitors Immunocore Competitors Kiniksa Pharmaceuticals Competitors Disc Medicine Competitors ARS Pharmaceuticals Competitors Edgewise Therapeutics Competitors Vera Therapeutics Competitors Travere Therapeutics Competitors Structure Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMLX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AMLX Stock Free AMLX Stock Alerts